YD Bio Ltd (YDES): Cash & Equivalents
$6.01M
As of 2025-12-31
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.01M | +91.8% | 2026-04-30, Balance as of period end |
| 2024-12-31 | $3.13M | n/a | 2026-04-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| YD Bio Ltd (YDES) | 2025-12-31 | $6.01M | +91.8% |
| Sera Prognostics, Inc. (SERA) | 2025-12-31 | $3.94M | -2.4% |
| Aclarion, Inc. (ACON) | 2025-12-31 | $12.02M | n/m |
| BioNexus Gene Lab Corp (BGLC) | 2025-12-31 | $2.49M | -13.9% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $3.46M | -68.6% |
| CapForce Inc. (CFOR) | 2025-12-31 | $531.3K | -59.5% |
| Exagen Inc. (XGN) | 2025-12-31 | $32.22M | +46.2% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $124.25M | +35.9% |
| Biodesix Inc (BDSX) | 2025-12-31 | $18.99M | -27.7% |
Compare YDES, SERA, ACON, BGLC side by side · Screen every company in Services-Medical Laboratories ↗